After going through pancreatic cancer chemotherapy for a while, a thought tends to come up at some point: "Aren't targeted therapies an option for us?" It's a word you hear all the time in conversations about lung or breast cancer, yet it rarely comes up with pancreatic cancer. The truth is, for a long time pancreatic cancer was called "a cancer that doesn't respond well to targeted therapy." But these days that statement doesn't fit quite as neatly as it used to. It isn't true for everyone, yet for some patients a real path has opened up.
The key question is whether genetic testing has been done. Some pancreatic cancers carry mutations in genes such as BRCA1 or BRCA2, and these patients tend to respond well to platinum-based chemotherapy. Once the disease has been brought under control with chemotherapy for a period of time, there is the option of using a drug like olaparib (a PARP inhibitor) as maintenance therapy. Beyond that, the situations where a tailored drug can be tried are slowly growing, even if they remain uncommon, such as NTRK fusions, KRAS G12C, and tumors that show certain immune markers. That said, patients who have one of these targets are a minority overall. So unless testing is done, there is no way to know.
For that reason, when you talk with your oncologist, it's worth asking once: "Is there any genetic testing that might be worth trying in our case?" This usually means a test like next-generation sequencing (NGS) done on tumor tissue or blood, and depending on the results, the available drug options may change. If no target turns up, that's disappointing, but it's not a loss either, because it also tells you the answer is to focus on the standard chemotherapy you are currently receiving.
It's completely natural to feel anxious deep down. Every time one chemotherapy regimen ends and you move on to the next drug, there's that nervous hope of "I wish this one works." Even so, it's a clear fact that treatment options keep being added, one line at a time, and simply holding on while keeping your condition stable is itself the greatest strength for catching the next opportunity. Eating well, cutting back on overly demanding schedules, and not enduring pain or digestive problems in silence but telling the medical team right away when they come up, all end up helping.
There are also quite a few drugs still in development, so if circumstances allow, looking into a clinical trial is one option as well. Still, all of this information should be judged together with the oncologist who is directly seeing the patient's condition, because even with the same pancreatic cancer, the answer differs from person to person.
This article is general information to aid understanding and does not replace professional medical advice. Treatment decisions must always be made in consultation with your attending physician.